« Back to Record
Citation APA

Subbiah, V., Braña, I., Longhi, A., Boni, V., Delord, J. P., Awada, A., Boudou-Rouquette, P., Sarantopoulos, J., Shapiro, G. G., Elias, A. A., Ratan, R., Fernández, C., Kahatt, C., Cullell-Young, M., Siguero, M., Zeaiter, A., & Chawla, S. (2022). Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. Clinical cancer research, 28(13), 2762-2770. doi:10.1158/1078-0432.CCR-22-0696


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/346873

Subbiah, V., Braña, I., Longhi, A., Boni, V., Delord, J. P., Awada, A., Boudou-Rouquette, P., Sarantopoulos, J., Shapiro, G. G., Elias, A. A., Ratan, R., Fernández, C., Kahatt, C., Cullell-Young, M., Siguero, M., Zeaiter, A., & Chawla, S. (2022). Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. Clinical cancer research, 28(13), 2762-2770. doi:10.1158/1078-0432.CCR-22-0696